CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.472
EU - Europa 2.284
AS - Asia 1.625
AF - Africa 40
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 6.434
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.459
CN - Cina 884
SG - Singapore 588
IT - Italia 479
RU - Federazione Russa 425
IE - Irlanda 288
FR - Francia 281
GB - Regno Unito 268
SE - Svezia 239
DE - Germania 167
FI - Finlandia 59
VN - Vietnam 50
TG - Togo 35
JP - Giappone 28
HK - Hong Kong 20
BE - Belgio 17
UA - Ucraina 16
ID - Indonesia 14
IN - India 10
CA - Canada 9
KR - Corea 9
NL - Olanda 9
TR - Turchia 9
ES - Italia 7
AT - Austria 5
BG - Bulgaria 4
LV - Lettonia 4
AR - Argentina 3
CH - Svizzera 3
CL - Cile 3
LT - Lituania 3
MX - Messico 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
EG - Egitto 2
EU - Europa 2
KG - Kirghizistan 2
PE - Perù 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CR - Costa Rica 1
IL - Israele 1
LK - Sri Lanka 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SC - Seychelles 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 6.434
Salva come PNG Salva come JPEG
Città #
Chandler 603
Singapore 491
Dublin 284
New York 249
Southend 245
Beijing 227
Ashburn 149
Lawrence 120
Princeton 120
Sindelfingen 102
Verona 96
Wilmington 95
Jacksonville 81
Jinan 62
Ann Arbor 56
Nanjing 47
Hebei 46
Woodbridge 46
Shenyang 44
Helsinki 42
Redwood City 41
Redmond 40
Lomé 35
Guangzhou 32
Dong Ket 29
Zhengzhou 29
Boardman 28
Haikou 26
Ningbo 24
Milan 23
Bologna 22
Norwalk 21
Rome 21
Kent 20
Seattle 20
Tokyo 20
Changsha 18
Taiyuan 17
Taizhou 16
Tianjin 16
Dallas 15
Hong Kong 15
Houston 15
Brussels 14
Hangzhou 14
Jakarta 14
Los Angeles 13
Nanchang 13
Jiaxing 12
Santa Clara 12
Lanzhou 10
Falls Church 9
Lappeenranta 9
Moscow 9
Seoul 9
Bari 8
Padova 8
Amsterdam 7
Palermo 7
Tombolo 7
Florence 6
Dongguan 5
Fairfield 5
Fuzhou 5
Naples 5
Washington 5
Ancona 4
Arco 4
Boston 4
Boydton 4
Brescia 4
Chicago 4
Delhi 4
Kemerovo 4
Pamplona 4
Riva 4
Sant'Ambrogio di Valpolicella 4
Sofia 4
Toronto 4
Treviso 4
Bollate 3
Busto Garolfo 3
Cambridge 3
Chions 3
Des Moines 3
Detroit 3
Istanbul 3
Las Vegas 3
London 3
Nashville 3
Negrar 3
Riyadh 3
San Diego 3
Texas City 3
Turin 3
Vienna 3
Abbiategrasso 2
Acquedolci 2
Altopascio 2
Barnet 2
Totale 4.066
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 199
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 96
Periostin: The bone and beyond 95
Fatal asthma; is it still an epidemic? 79
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 76
Allergic rhinitis: pharmacotherapy in pregnancy and old age 70
Omalizumab management beyond clinical trials: the added value of a network model 69
What lies beyond Asthma Control Test: Suggestions for clinical practice 69
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 69
Adverse reaction to local anaesthetics: Is it always allergy? 69
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 68
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 66
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 66
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 66
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 65
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 62
Asthma management among different specialists: results from a national Italian survey 62
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 62
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 62
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 61
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 61
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 60
Biologic Therapy in a Patient with Asthma and Nasal Polyps 58
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 58
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 57
Towards precision medicine: The application of omics technologies in asthma management 56
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 56
COPD prevalence in a north-eastern Italian general population 55
Biologics and global burden of asthma: A worldwide portrait and a call for action 55
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 54
Occupational rhinitis to sodium alendronate 54
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 54
Uncontrolled Asthma: Unmet Needs in the Management of Patients 54
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 53
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 53
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 53
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 53
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 52
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 51
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 51
Severe refractory asthma: current treatment options and ongoing research 51
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 51
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 51
Asthma management among allergists in Italy: results from a survey 51
BCG vaccination and COVID-19: Much ado about nothing? 51
Allergy and Sexual Behaviours: an Update 50
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 50
Biologic Therapy in a Patient with Asthma and Nasal Polyps 49
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 49
Quality of life in patients with food allergy 49
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 49
Asthma and anaphylaxis 49
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 49
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 48
Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in Northern Italy general population 48
Targeting eosinophils: severe asthma and beyond 47
Anxiety and Depression Effects During Drug Provocation Test 47
Emerging drugs for allergic conjunctivitis 47
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 47
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 46
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 46
Anaphylaxis and intimate behaviour 46
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 45
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 44
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 44
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 44
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 43
Sex in Respiratory and Skin Allergies 43
Biologics for the Treatments of Allergic Conditions 43
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry 43
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 43
The role of the pharmacy in the management of bronchial asthma: A literature-based evaluation 42
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 42
Usefulness of basophil activation test in diagnosis of occupational nonasthmatic eosinophilic bronchitis 42
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 42
Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology? 41
Italian study on buckwheat allergy: prevalence and clinical features of buckwheat-sensitized patients in Italy 40
Vitamin B12 and Atopic Dermatitis: Any Therapeutic Relevance For Oral Supplementation? 40
Use of complementary medicine among patients with allergic rhinitis: an Italian nationwide survey. 39
Occupational eosinophilic bronchitis: Considerations and new diagnostic instruments in the margins of a clinical case. [La bronchite eosinofila professionale: Considerazioni e nuovi strumenti diagnostici a margine di un caso clinico] 39
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 39
Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine? 39
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 39
The EAACI-AAAAI-WAO Junior Members' joint survey: A worldwide snapshot of Allergy and Clinical Immunology specialty 38
Type 2 immunity in asthma 37
Safety and tolerability of sublingual immunotherapy in clinical trials and real life 37
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 37
Respiratory allergies in childhood: Recent advances and future challenges 36
Reconsidering anaphylaxis at the time of COVID-19 pandemic 36
Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients 35
Management of chronic spontaneous urticaria: a worldwide perspective 35
Effects of sublingual immunotherapy on allergic inflammation: an update 35
One year of mepolizumab. Efficacy and safety in real-life in Italy 35
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 35
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 35
OCCUPATION study (OCCUPationl asthma: a naTIONal based study): a survey on occupational asthma awareness among Italian allergists 34
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 33
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 33
COVID-19 pandemic and environment: Not only air pollution 33
Immune Mechanisms of Allergen-Specific Immunotherapy 33
Totale 5.173
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.695
article - articoli 34.695
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.390
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020377 0 0 0 0 40 28 8 2 3 153 101 42
2020/2021697 77 125 23 83 144 77 17 23 20 9 45 54
2021/2022714 94 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20251.177 177 215 155 507 123 0 0 0 0 0 0 0
Totale 6.648